Setbacks For China Pharma As Firms Hit With Antitrust Fine, Clinical Setback
One of China's largest domestic pharma conglomerates has been fined more than $100m for price-fixing and other monopoly acts, while another firm has seen a major Phase III setback for its global launch hope.
You may also be interested in...
Growing over 9% and domestic study sponsors take over 70% of the drugs in different stages, China clinical study sector attracts renewed interests post COVID, but underneath an uneven and less efficient field, noted a just released regulatory report.
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.